within Pharmacolibrary.Drugs.ATC.B;

model B02AA02_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 1.8333333333333333,
    adminDuration  = 600,
    adminMass      = 1.0,
    adminCount     = 1,
    Vd             = 0.009,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005666666666666667,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Tranexamic acid is an antifibrinolytic agent that inhibits plasminogen activation, thereby preventing fibrinolysis and stabilizing blood clots. It is primarily used to treat or prevent excessive bleeding in various medical conditions, including during surgery, trauma, heavy menstrual bleeding (menorrhagia), and in certain bleeding disorders. Tranexamic acid is approved for use in many countries worldwide.</p><h4>Pharmacokinetics</h4><p>Oral administration in healthy adult volunteers.</p><h4>References</h4><ol><li>Andrea Cortegiani, Anthony R Absalom, Beverley J Hunt,Intramuscular tranexamic acid: a real-world application of pharmacokinetics.,British journal of anaesthesia,2021<a href='https://pubmed.ncbi.nlm.nih.gov/33131654/'>https://pubmed.ncbi.nlm.nih.gov/33131654/</a></li><li>Sixtine Gilliot, Anne-Sophie Ducloy-Bouthors, Florence Loingeville, Benjamin Hennart, Delphine Allorge, Gilles Lebuffe, Pascal Odou,Pharmacokinetics of Curative Tranexamic Acid in Parturients Undergoing Cesarean Delivery.,Pharmaceutics,2022<a href='https://pubmed.ncbi.nlm.nih.gov/35335955/'>https://pubmed.ncbi.nlm.nih.gov/35335955/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B02AA02_1;
